RecruitingPhase 2NCT05727176
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Oncology, Inc.
- Intervention
- TAS-120(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- University of California San Diego UCSD - Moores Cancer Center, La Jolla, California, United States
- Tampa General Hospital Cancer Institute, Tampa, Florida, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Gabrail Cancer Center Research, Canton, Ohio, United States
- Texas Oncology, Abilene, Texas, United States
- The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
- Texas Oncology Methodist DFW, Dallas, Texas, United States
- Texas Onc Methodist (Charlton), Dallas, Texas, United States
- Texas Oncology - Northeast, Denton, Texas, United States
- Center for Oncology and Blood Disorders, Houston, Texas, United States
- Hospital Britanico, Buenos Aires, Argentina
- CEMIC, CABA, Argentina
- Sanatorio de la Mujer, Rosario, Argentina
- St Vincent's Hospital Sydney - The Kinghorn Cancer Centre, Sydney, New South Wales, Australia
- Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center, Melbourne, Victoria, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05727176 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University